| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1517/17425255.2011.585156 |
| P698 | PubMed publication ID | 21563999 |
| P50 | author | Gennaro Daniele | Q37828894 |
| Nicola Normanno | Q37828910 | ||
| Antonella De Luca | Q39048942 | ||
| Marianna Gallo | Q81350050 | ||
| Monica Rosaria Maiello | Q104516503 | ||
| Amelia D'Alessio | Q116998254 | ||
| Luana Lamura | Q116998255 | ||
| Pasqualina Giordano | Q116998256 | ||
| Maria Pergameno | Q116998257 | ||
| P2093 | author name string | Francesco Perrone | |
| P2860 | cites work | Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma | Q33215107 |
| A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma | Q34152748 | ||
| Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies | Q34247899 | ||
| Endocrine therapy plus zoledronic acid in premenopausal breast cancer. | Q34943802 | ||
| Antitumor effects of bisphosphonates | Q35053955 | ||
| Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells | Q35458425 | ||
| Recommendations for zoledronic acid treatment of patients with bone metastases | Q35999713 | ||
| Human Vgamma9Vdelta2 T cells: promising new leads for immunotherapy of infections and tumors | Q36548005 | ||
| Molecular mechanisms of action of bisphosphonates: current status. | Q36633778 | ||
| Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates | Q37179393 | ||
| Potential anticancer properties of bisphosphonates. | Q37777494 | ||
| Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients | Q37800176 | ||
| Zoledronic acid induces formation of a pro-apoptotic ATP analogue and isopentenyl pyrophosphate in osteoclasts in vivo and in MCF-7 cells in vitro | Q39860282 | ||
| Cytosolic entry of bisphosphonate drugs requires acidification of vesicles after fluid-phase endocytosis | Q40311684 | ||
| Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model | Q40538169 | ||
| A dose-finding study of zoledronate in hypercalcemic cancer patients | Q40799250 | ||
| Bisphosphonates: a review of their pharmacokinetic properties | Q41132404 | ||
| Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model | Q41497465 | ||
| Peripheral blood monocytes are responsible for gammadelta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. | Q42183397 | ||
| Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound | Q42283820 | ||
| Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients | Q42516923 | ||
| Zoledronate Stimulates γδ T Cells in Prostate Cancer Patients | Q42948400 | ||
| Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid | Q44020395 | ||
| Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid | Q44106382 | ||
| Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases | Q44202473 | ||
| The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function | Q44343595 | ||
| Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group | Q44547450 | ||
| Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial | Q44611376 | ||
| Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial | Q44937090 | ||
| Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. | Q46028184 | ||
| Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy | Q46417627 | ||
| Antitumor effects of doxorubicin followed by zoledronic acid in a mouse model of breast cancer. | Q46434787 | ||
| Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. | Q46482917 | ||
| Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. | Q46801197 | ||
| Antitumor effects of clinical dosing regimens of bisphosphonates in experimental breast cancer bone metastasis. | Q50696322 | ||
| Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase | Q54976416 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pharmacokinetics | Q323936 |
| P304 | page(s) | 911-918 | |
| P577 | publication date | 2011-05-13 | |
| P1433 | published in | Expert Opinion on Drug Metabolism & Toxicology | Q5421205 |
| P1476 | title | Pharmacokinetic evaluation of zoledronic acid | |
| P478 | volume | 7 |
| Q37993568 | Bisphosphonate related osteonecrosis of the jaws: a review |
| Q53743085 | Models for anti-tumor activity of bisphosphonates using refined topochemical descriptors. |
| Q37577433 | Panobinostat synergizes with zoledronic acid in prostate cancer and multiple myeloma models by increasing ROS and modulating mevalonate and p38-MAPK pathways. |
| Q35919801 | Urinary N telopeptide levels in predicting the anti-nociceptive responses of zoledronic acid and paclitaxel in a rat model of bone metastases |
| Q36395911 | Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB |
Search more.